Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?

Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?

CLICK HERE FOR CME CREDIT

Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology Université Paris – Diderot, Sorbonne-Paris Cité Professor, National Heart and Lung Institute Imperial College, London, UK Director, Coronary Care Unit Hôpital Bichat Paris, France